[{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Gesynta Pharma"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cereno Scientific Obtains IND Acceptance from FDA to Start Phase II Study with Drug Candidate CS1 in PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cereno Scientific"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplifier Therapeutics, a Cambrian Bio Pipeline Company, Doses First Patients in Phase 1B Clinical Trial and Closes New Financing from Future Ventures and RA Capital Management","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Amplifier Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
ATX-304 is a peripherally acting pan-AMPK activator with beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of metabolic disorders, as well as cardiovascular function.
CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.
The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.